Although there is no method of cure chronic hepatitis B virus (HBV) infection, the antiviral treatment strategy of interferon (IFN) or nucleoside analog (NA) can effectively control the virus.
Therefore, the treatment of chronic hepatitis B is to continuously inhibit virus replication, thereby reducing the risk of fibrotic progress and reducing the risk of liver cell carcinoma (HCC).
The ideal treatment of patients with the Three -Yangyang patients is to become Xiao Sanyang; this sometimes causes the hepatitis B surface antigen (HBSAG) to turn yin, which is considered to be closest to clinical cure chronic hepatitis B virus infection.
Instead, the only ending point of the patient with Xiaoyang is HBSAG turning.Since the current drugs are rarely achieved, it is usually necessary for lifelong treatment of HBEAG negative patients.
Pregnant women with high virus load can significantly reduce the risk of vertical transmission of newborn
This is of great significance to reduce the chronic infection of new hair HBV
Today, Vili does not want to discuss with you when the expectant mothers should use medicine and how to use medicine. First of all, these have told you in the past.In addition, follow the doctor’s advice.Today Vili wants to introduce the long -term clinical ending of women during pregnancy after pregnancy.If you have recurrence after stopping the drug, whether you can convert to Xiaoyang Yang, etc., you are very concerned.
The study was published in October this year to explore the long -term ending of slow -hepatitis B women during pregnancy or treatment of norofovir ester (TDF).
Studies have been treated with TDF-treated or not treated with TDF from 2011 to 2019 to conduct retrospective practical research, collect data such as AlT, HBV-DNA, HBEAG, liver hardness during pregnancy and postpartum.
The results showed that the 341 women who were included in the study had an average of 33 months after delivery.Among them, 19%(65/341) received TDF treatment.Among all women who received TDF treatment, the HBV DNA declined during treatment, but HBV DNA picked up after the TDF was discontinued.Among the patients of the big Sanyang (65/341), the ALT rebound is more common (P = 0.03), especially patients with TDFs who have discontinued TDFs, and 11 of them need to be treated again.In contrast, 54%(116/215) without treatment has an increase in ALT after delivery; a woman with severe hepatitis has been transplanted 13 months after giving birth.
The average follow -up of postpartum follow -up is 33 months, which is equivalent to more than two and a half years. The length is enough to let us see the long -term ending of taking or not taking TDF during pregnancy.From the above data, we can see that for patients with hepatitis B, postpartum ALT seizures are more common, especially after stopping TDF.For pregnant women with hepatitis B, although the HBV DNA rebounded after postpartum, it did not rebound the level before the medication.37%of the patients who were included in the research reached HBEAG removal in long -term follow -up, and 2.9%got the gold medal loss.
I often ask me in the group, when will the medicine stop after taking the medicine during pregnancy?Will it rebound after stopping the drug.It can be seen from this study that ALT rebounding after stopping the drug is very common.Whether to stop the medicine, when to stop the medicine, and whether to take the medicine after rebounding or not to discuss with your attending physician in detail.
